Claims for Patent: 6,555,156

Summary for Patent: 6,555,156

Title:	Process for making absorbable microparticles
Abstract:	The invention pertains to a process for making encased bound microparticles by nebulizing a dispersion of the bound microparticles into a solution of an encasing polymer and into a liquid, non-solvent of said encasing polymer.
Inventor(s):	Loughman; Thomas Ciaran (Dublin, IE)
Assignee:	Kinerton Limited (Dublin, IE)
Application Number:	09/601,074
Patent Claims:	1. A process for making an encased bound microparticle or microparticles wherein the encased bound microparticle or microparticles comprise bound microparticle or microparticles and an absorbable encasing polymer where the bound microparticle or microparticles comprise an absorbable heterochain polymer core and one or more peptide, one or more protein or a combination thereof ionically immobilized on said absorbable heterochain polymer core where each peptide is independently selected from growth hormone releasing peptide (GHRP), luteinizing hormone-releasing hormone (LHRH), somatostatin, bombesin, gastrin releasing peptide (GRP), calcitonin, bradykinin, galanin, melanocyte stimulating hormone (MSH), growth hormone releasing factor (GRF), amylin, tachykinins, secretin, parathyroid hormone (PTH), enkaphelin, endothelin, calcitonin gene releasing peptide (CGRP), neuromedins, parathyroid hormone related protein (PTHrP), glucagon, neurotensin, adrenocorticothrophic hormone (ACTH), peptide YY (PYY), glucagon releasing peptide (GLP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating peptide (PACAP), motilin, substance P, neuropeptide Y (NPY), TSH and analogs and fragments thereof or a pharmaceutically acceptable salt thereof; and where each protein is independently selected from growth hormone, erythropoietin, granulocyte-colony stimulating factor, granulocyte-macrophage-colony stimulating factor and interferons; said process comprising the steps of: obtaining a dispersion, where the dispersion comprises solid bound microparticles in a solution of the absorbable encasing polymer, by homogenizing and concurrently dispersing said solid bound microparticles into the solution of an absorbable encasing polymer; and nebulizing said dispersion through a nebulization probe into a liquid, non-solvent of said absorbable encasing polymer at a flow rate of about 1 ml/min to 15 ml/min wherein said non-solvent is maintained at a temperature of about room temperature to about -80.degree. C. and said probe has an operating ultrasonic frequency range of 12 kHz to 36 kHz. 2. A process according to claim 1 wherein said medium comprises isopropanol or ethanol. 3. A process according to claim 2 wherein the solution of the absorbable polymer consists of about 5% to 30% of the absorbable polymer. 4. A process according to claim 1 wherein the peptide, peptides, protein or proteins or combination thereof of the bound microparticle comprises 0.1% to 30% of the total mass of the bound microparticle. 5. A process according to claim 4 wherein the absorbable polymer core comprises glycolate units and citrate residues wherein the ratio of glycolate units to citrate residues is about 7-1 to about 20-1 or glycolate units and tartrate residues wherein the ratio of glycolate units to tartrate residues is about 7-1 to about 20-1 or glycolate units and malate residues wherein the ratio of glycolate units to malate residues is about 7-1 to about 20-1. 6. A process according to claim 5 wherein absorbable encasing polymer comprises (a) l-lactide based units and glycolide based units where the ratio of l-lactide based units to glycolide based units is about 60-40 to about 90-10, (b) d,l-lactide based units and glycolide based units where the ratio of d,l-lactide based units to glycolide based units is about 60-40 to about 90-10, (c) d,l-lactide based units, or (d) l-lactide based units and d,l-lactide based units where the ratio of l-lactide based units to d,l-lactide based units is about 80-20. 7. A process according to claim 6 wherein the absorbable encasing polymer constitutes 5 to 70% of the total mass of the encased bound microparticle or microparticles. 8. A process according to claim 7 wherein the absorbable encasing polymer constitutes 20-60% of the total mass of the encased bound microparticle or microparticles. 9. A process according to claim 8 wherein the absorbable encasing polymer constitutes 30-50% of the total mass of the encased bound microparticle or microparticles. 10. A process according to claim 9 where the peptide is an LHRH analog. 11. A process according to claim 10 where the LHRH analog is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2. 12. A process according to claim 9 where the peptide is a somatostatin analog. 13. A process according to claim 12 where the somatostatin analog is H-.beta.-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH.sub.2, where the two Cys are bonded by a disulfide bond. 14. A process according to claim 12 where the somatostatin analog is N-hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH. sub.2 where the two Cys residues are bonded by a disulfide bond. 15. A process according to claim 12 where the somatostatin analog is N-hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr- NH.sub.2 where the two Cys residues are bonded by a disulfide bond.

Details for Patent 6,555,156

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26